Phaseline

Companies › Keystone Nano

Keystone Nano: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ceramide NanoLiposome (Ceraxa)
C6 ceramide nanoliposome
–Phase 1Acute Myeloid Leukemia, in RelapseJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04716452Ceramide NanoLiposome (Ceraxa)Phase 1Acute Myeloid Leukemia, in RelapseOncologyJan 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.